Neochem Bio Solutions Limited is a specialty performance chemicals manufacturer offering 350+ customized formulations across polymers, surfactants, silicones, esters and bio-based sustainable solutions. The company earns revenue by supplying customized chemicals to textile, home & personal care, industrial cleaning, paper, paints, water treatment and construction industries. Its products serve as critical functional additives improving strength, finishing, processing efficiency and lifecycle performance of end-use products.

The Company is led by Promoter, i.e., SWAPNIL RAMESHBHAI MAKATI AND HEMANGINI SWAPNIL DATHIA

The Revenues from operations for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 4,718.16 Lakh, ₹ 8,615.35 Lakh, ₹ 6,200.75 Lakh, and ₹ 4,879.03 Lakh, The EBITDA for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹859.22 Lakh, ₹ 1,311.29 Lakh, ₹ 599.01 Lakh, and ₹ 422.84 Lakh, The Profit after Tax for the Period ended on Sep 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 548.38 Lakh, ₹ 775.06Lakh, ₹ 180.13 Lakh, and ₹ 107.29 Lakh, respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue EPS of ₹6.64 and post-issue EPS of ₹4.53 for FY25. The pre-issue P/E ratio is 14.76x,while the post-issue P/E ratio is 21.65x against the Industry P/E ratio is 17.42x The company's ROE for FY25 is 48.82% and RoNW is 48.82% The Annualised EPS is ₹6.41x and P/E is 15.30x. These metrics suggest that the IPO is Fully priced.

The Grey Market Premium (GMP) of Neochem Bio Solutions showing listing gains of  0%.Given the company's financial performance and the valuation of the IPO, we recommend  Investors to Avoid to the Neochem Bio Solutions Limited IPO for Listing gain or Long Term Purposes.